GILD Feb 2025 62.500 call
| Previous Close | 25.72 |
| Open | 25.72 |
| Bid | 21.65 |
| Ask | 25.10 |
| Strike | 62.50 |
| Expire Date | 2025-02-21 |
| Day's Range | 25.72 - 25.72 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 6 |
GuruFocus.comGilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ...
Gilead Sciences Inc (GILD) reports robust financial performance with significant sales growth in key therapeutic areas and raises full-year guidance.
Business WireGilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
FOSTER CITY, Calif., October 09, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2024 financial results and guidance will be released on Wednesday, November 6, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2024 financial results and provide a business update.
Business WireGilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
FOSTER CITY, Calif., October 09, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek 2024, taking place from October 16-19. The data from 31 presentations across HIV treatment and prevention, COVID-19 and viral hepatitis include one late breaker abstract and six oral presentations, reflecting Gilead’s commitment to helping address the evolving needs of a diverse range of people and com
